List view / Grid view
26 April 2016 | By Victoria White, Drug Target Review
In an exclusive interview, Trevor Perrior, Research Director at Domainex, discusses the cell death regulatory protein FLIP and the potential of FLIP inhibitors as a treatment for NSCLC...
26 April 2016 | By Victoria White, Digital Content Producer
Queen’s University Belfast and Domainex have secured an award to advance therapeutic candidate molecules into clinical evaluation for treatment of NSCLC...
19 April 2016 | By Victoria White, Digital Content Producer
Johnson Matthey and Domainex have announced a collaboration to provide integrated small molecule pharmaceutical discovery and development services...
3 February 2016 | By Victoria White
This award will give Dr Echalier access to the drug discovery capabilities of Domainex in support of her research...
25 January 2016 | By Victoria White
The alliance will give clients access to the expertise of Domainex in protein expression, biochemical assays, hit identification, computational and medicinal chemistry; and to Cresset’s approach to hit identification and drug design...
29 October 2015 | By Victoria White
Domainex is expanding all aspects of its drug discovery service business including biology, analytical chemistry and medicinal chemistry...
20 October 2015 | By Victoria White
Domainex has been selected as Imperial’s strategic drug discovery partner to provide services including biochemical and biophysical assay development...
15 September 2015 | By
Since initiating the project in 2014, significant progress has been made towards the invention of new compounds with activity against both gram-positive and gram-negative bacteria...
11 May 2015 | By Victoria White
US and EU Patent Offices have granted Domainex patents for the first generation of inhibitor compounds in its lead programme targeting IKK epsilon and TBK1.
10 December 2014 | By ZoBio and Domainex
ZoBio (Leiden, The Netherlands) and Domainex Ltd. (Cambridge, UK) announce a collaboration with FORMA Therapeutics (Watertown, MA, USA) to provide NMR-based structural biology services for a substantial panel of FORMA drug targets...
15 October 2014 | By Domainex
Domainex Ltd. and Auspherix Pty Ltd announced a collaboration that will progress Auspherix’s novel anti-infective drug discovery programme towards the nomination of a clinical candidate...
9 July 2014 | By Domainex
Domainex Ltd announced that its lead compound has demonstrated a more potent effect in a key model of chronic obstructive pulmonary disease than either roflumulast or a p38 inhibitor...
